Is the modulatory effect of pregnancy in multiple sclerosis associated with changes in blood apoptotic molecules?

Acta Neurologica Scandinavica

Volumn 122, Issue 3, 2010, Pages 168-174

  Rinta, S ^a   Airas, L ^c   Elovaara, I ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Fas; Fas ligand; macrophage migration inhibitory factor; Multiple Sclerosis; Pregnancy; TNF related apoptosis inducing ligand

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PREGNANCY; PUERPERIUM; RELAPSE; RISK ASSESSMENT; UPREGULATION;

ADULT; ANTIGENS, CD95; CELL MIGRATION ASSAYS, MACROPHAGE; CYTOKINES; FAS LIGAND PROTEIN; FEMALE; HUMANS; MULTIPLE SCLEROSIS; POSTPARTUM PERIOD; PREGNANCY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 77955286007     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01301.x     Document Type: Article

References (38)

1. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998 339 : 285 291.
2. Kruse N, Greif M, Moriabadi NF, Marx L, Toyka KV, Rieckmann P. Variations in cytokine mRNA expression during normal human pregnancy. Clin Exp Immunol 2000 119 : 317 322.
3. Marzi M, Vigano A, Trabattoni D et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996 106 : 127 133.
4. Gilmore W, Arias M, Stroud N, Stek A, Mccarthy KA, Correale J. Preliminary studies of cytokine secretion patterns associated with pregnancy in MS patients. J Neurol Sci 2004 224 : 69 76.
5. Saraste M, Ryynanen J, Alanen A et al. Cerebrospinal fluid findings in multiple sclerosis patients before, during and after pregnancy. J Neurol Neurosurg Psychiatry 2006 77 : 1195 1196.
6. Van Den Broek HH, Damoiseaux JG, De Baets MH, Hupperts RM. The influence of sex hormones on cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis: a review. Multiple Sclerosis (Houndmills, Basingstoke, England) 2005 11 : 349 359.
7. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007 28 : 521 574.
8. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993 14 : 353 356.
9. Saraste M, Vaisanen S, Alanen A, Airas L. Clinical and immunologic evaluation of women with multiple sclerosis during and after pregnancy. Gend Med 2007 4 : 45 55.
10. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004 112 : 38 43.
11. Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 2008 151 : 235 243.
12. Offner H, Polanczyk M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann NY Acad Sci 2006 1089 : 343 372.
13. Rinta S, Kuusisto H, Raunio M et al. Apoptosis-related molecules in blood in multiple sclerosis. J Neuroimmunol 2008 205 : 135 141.
14. Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998 351 : 978 981.
15. Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 1998 86 : 151 154.
16. Macchi B, Matteucci C, Nocentini U, Caltagirone C, Mastino A. Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport 1999 10 : 399 402.
17. Zang YC, Kozovska MM, Hong J et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol 1999 29 : 1692 1700.
18. Sharief MK. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. J Neuroimmunol 2000 109 : 236 243.
19. Semra YK, Seidi OA, Sharief MK. Disease activity in multiple sclerosis correlates with T lymphocyte expression of the inhibitor of apoptosis proteins. J Neuroimmunol 2002 122 : 159 166.
20. Sharief MK, Matthews H, Noori MA. Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis. J Neuroimmunol 2003 134 : 158 165.
21. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 2004 55 : 410 417.
22. Ehrlich S, Infante-Duarte C, Seeger B, Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 2003 24 : 244 253.
23. Diehl GE, Yue HH, Hsieh K et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004 21 : 877 889.
24. Lunemann JD, Waiczies S, Ehrlich S et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002 168 : 4881 4888.
25. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001 166 : 1314 1319.
26. Dorr J, Roth K, Zurbuchen U et al. Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate. J Neuroimmunol 2005 167 : 204 209.
27. Nitsch R, Bechmann I, Deisz RA et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000 356 : 827 828.
28. Aktas O, Smorodchenko A, Brocke S et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005 46 : 421 432.
29. Wandinger KP, Lunemann JD, Wengert O et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003 361 : 2036 2043.
30. Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 2005 105 : 1396 1404.
31. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science (New York, NY) 1994 263 : 1759 1762.
32. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997 186 : 2045 2050.
33. Lopatinskaya L, Van Boxel-Dezaire AH, Barkhof F, Polman CH, Lucas CJ, Nagelkerken L. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. J Neuroimmunol 2003 138 : 123 131.
34. Ehrlich S, Haas J, Zipp F, Infante-Duarte C. Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancy. J Neurol Sci 2007 252 : 83 7.
35. Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000 179 : 127 131.
36. Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 2005 35 : 419 426.
37. Denkinger CM, Denkinger M, Kort JJ, Metz C, Forsthuber TG. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003 170 : 1274 1282.
38. Elenkov IJ, Wilder RL, Bakalov VK et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 2001 86 : 4933 4938.